,
Nowadays, the appropriate control of rheumatoid arthritis (RA) involves the absence of clinical disease activity, delaying joint destruction as long as possible and adequate quality of life of the affected. With currently available therapeutic modalities, this therapeutic goal can be achieved in a large number of patients. The aim of this research was to determine the effectiveness of an IL-6 blocker (Tocilizumab) in patients with RA in everyday clinical practice. We also analyzed whether a change in the mode of drug administration (switching from intravenous to subcutaneous drug formulation) had an impact on drug effectiveness (using the DAS 28 SE and CDAI indexes) and quality of life of patients with RA (HAQ, Beck Depression Inventory, FACIT F score and SF 36 questionnaire). The study included 53 subjects diagnosed with RA, treated with Tocilizumab. After a six-month use of subcutaneous Tocilizumab, we concluded that the method of drug administration did not have an impact on its effectiveness and on all the examined parameters of quality of life assessment.
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
3
Giorgio Galoppini, Carlo Garaffoni, Andrea Lotesoriere, Federico Nogarin, Alessandra Bortoluzzi, Marcello Govoni, Ettore Silvagni
(2025)
Switch from Intravenous to Subcutaneous Formulation of Tocilizumab in Rheumatoid Arthritis: Retrospective Cohort Analysis and Systematic Literature Review
Biologics: Targets and Therapy, Volume 19()
10.2147/BTT.S555169
Nikola Krstić, Nikola Stefanović, Milan Petronijević, Ivana Damnjanović
(2024)
Polypharmacy and the risk of drug-drug interactions in patients with rheumatoid arthritis
AFMN Biomedicine, 41(2)
10.5937/afmnai41-45883
Soo Min Ahn, Ji Seon Oh, Hyun Mi Heo, Seokchan Hong, Chang-Keun Lee, Bin Yoo, Yong-Gil Kim
(2022)
Predictive Factors for Rheumatoid Arthritis Flare After Switching From Intravenous to Subcutaneous Formulation of Tocilizumab in Real-World Practice
Journal of Korean Medical Science, 37(17)
10.3346/jkms.2022.37.e138The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.